5AM Ventures V, L.P. sold $807K of TRDA
5AM Ventures V, L.P. sold 116,474 shares of Entrada Therapeutics, Inc. (TRDA) at an average of $6.93 ($6.85–$6.93, $0.81M total) across 2 trades over 2026-07-30 to 2026-07-31.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the open-market sale of 116,474 shares by a 10% owner at $6.8500 to $6.9300 per share, totaling about $807K, with holdings after the sale of 2,846,592 shares.
Market read
Traders may briefly reassess sentiment around TRDA due to insider selling, but there is no fundamental catalyst in the text.
What to watch
The absence of a stated 10b5-1 plan can increase perceived signal, but the article provides no context on why the sale occurred or whether other insiders are buying.
Background
The article is an SEC Form 4 insider transaction for Entrada Therapeutics, Inc. (TRDA).
Ticker impact
Entrada Therapeutics Form 4 shows 5AM Ventures V, L.P., a 10% owner, sold 116,474 TRDA shares for about $807K in late July.
Likely limited near-term impact; any effect would be sentiment-driven rather than a new company catalyst.
The filing is a primary SEC Form 4 disclosure, but it contains no earnings, guidance, trial, deal, or regulatory update, only an open-market sale and remaining holdings.
Market effects
No direct sector read-through because the disclosure is company-specific and lacks operational or clinical details.
None indicated.
None indicated.
Counterpoint
A large 10% owner sale can be liquidity-driven (taxes, diversification) and may not reflect negative expectations, especially without any accompanying negative company news.
Key entities
- issuerEntrada Therapeutics, Inc.
TRDA, subject of the Form 4 insider transaction disclosure.
- insider5AM Ventures V, L.P.
10% owner who executed the open-market sale.
